SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

Approaching Sarcoidosis Therapy From a 21st Century Perspective

CHEST 2022 Coverage

D. Culver

ECG Interpretation: Everything You Need to Know to Understand and In…

Houston Methodist DeBakey Heart and Vascular Center

A. Dave

EHRA 2024: Ongoing Clinical Investigations with Cardiac Contractilit…

CCM® Therapy

N. Varma

Implementation of Drug Therapies for Heart Failure with Reduced Ejec…

Michigan Medicine

J. Golbus

EHRA 2024: Real-World Experience with Cardiac Contractility Modulati…

CCM® Therapy

J. Kuschyk

The Best of AHA23 for the Primary Care Doctor

Cecilia Bahit

Advances and Updates in Sarcoidosis: Diagnosis and Treatment of Pulm…

UCLA Health

J. Belperio

Sarcoidosis: Diagnosis and Management

University of Colorado Department of Medicine

N. Held

Heart Failure Case Presentations

San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians

B. Greenberg, G. Fonarow, N. Wettersten, M. Rosa Costanzo

EHRA 2024: Cardiac Contractility Modulation: Innovative Therapy for …

CCM® Therapy

V. Reddy, N. Varma, K. Kuck, J. Kuschyk, N. Aspromonte

Coronary Microvascular Disease in HFpEF: Pathophysiology, Diagnosis …

MUSC Cardiology

S. Mohammed

Digoxin Update 2023: Are the Current Digoxin Monitoring Guidelines H…

Mary E. Money

Musculoskeletal Pathology as an Early Warning Sign of Systemic Amylo…

Houston Methodist

S. Liberman

ATS 2023 Insights: To PAP or Not to PAP - Heart Failure and Sleep Di…

Vaishnavi Kundel

V. Kundel

SOHO 2022: Amyloidosis - Update and How To Use Novel Agents

SOHO 2022 Tenth Annual Meeting

S. Lentzsch

EHRA 2024: Unmet Medical Needs in Heart Failure Management: Can Devi…

CCM® Therapy

N. Aspromonte